Telix has agreed to acquire ITM Isotope Technologies Munich for $1.65 billion upfront, according to Fierce Biotech. The deal brings in an R&D pipeline anchored by a candidate that could compete directly with Novartis' Lutathera, a key product in the radiopharmaceutical market.
The acquisition also includes ITM's radiopharmaceutical supply network, which analysts say strengthens Telix's position in the space. The deal is seen as a strategic move into territory where Novartis has been a major player.
Analysts are described as 'extremely bullish' on the transaction, citing both the pipeline and the supply infrastructure. The deal highlights growing competition in targeted cancer therapies and radiopharmaceutical manufacturing.